Alphabet's AI Drug Discovery Firm Secures $2.1 Billion to Accelerate Clinical Trials
Isomorphic Labs, a leading AI drug research company, has raised $2.1 billion in Series B funding to scale its AI platform for drug development and push its pipeline of drug candidates closer to clinical trials. This significant investment will enable the company to expand its global presence and accelerate its mission to solve all diseases using AI-powered drug discovery.
Isomorphic Labs, the AI drug research company led by DeepMind co-founder Demis Hassabis, has closed a $2.1 billion Series B round led by Thrive Capital. The funding will go toward expanding its in-house platform IsoDDE and advancing drug candidates toward clinical trials. The article Alphabet's Isomorphic Labs raises $2.1 billion to scale AI drug discovery toward clinical trials appeared first on The Decoder.